What is the target AUC/MIC for vancomycin?

The target AUC₂₄/MIC is 400–600, assuming a MIC of 1 mg/L (which covers most MRSA). AUC <400 may lead to treatment failure, while AUC >600 is associated with increased nephrotoxicity risk. For serious MRSA infections (bacteremia, endocarditis, osteomyelitis, pneumonia), maintaining AUC 400–600 is critical per the 2020 ASHP/IDSA/SIDP consensus guidelines.

How is vancomycin dose adjusted for kidney disease?

Vancomycin clearance directly parallels renal function. Dose adjustment is based on creatinine clearance (CrCl): CrCl >90 mL/min → 15–20 mg/kg q8-12h; CrCl 50–90 → q12h; CrCl 30–50 → q24h; CrCl 15–30 → q48h; CrCl <15 or ESRD → dose by levels (q72-96h or after HD sessions). In AKI, CrCl may change rapidly — increase monitoring frequency. Calculate CrCl using [Creatinine Clearance Calculator](/tools/creatinine-clearance). Always involve pharmacy for complex renal dosing.

How is vancomycin dosed for hemodialysis patients?

Hemodialysis (HD) removes approximately 30–50% of vancomycin per session with high-flux membranes. Standard approach: give 15–20 mg/kg IV (loading dose) initially. Check a pre-HD vancomycin level before subsequent sessions — if below 10–15 mcg/mL, supplement with 500–1000 mg post-HD. Because HD patients have minimal or no residual renal function, vancomycin half-life is very long (100–250 hours). Pharmacist guidance is essential. For CRRT (continuous renal replacement), dosing is more predictable — typically q12-24h based on effluent rate.

How long should vancomycin be given for bacteremia?

Duration of vancomycin therapy for MRSA bacteremia: uncomplicated bacteremia (source removed, negative repeat cultures at 48–72h, no endocarditis/metastatic focus, no prosthetic material) requires a minimum of 14 days of IV vancomycin. Complicated bacteremia (endocarditis, osteomyelitis, septic arthritis, prosthetic device, or persistent bacteremia after source control) requires 4–6 weeks. Repeat blood cultures at 48–72 hours are mandatory to document clearance — persistent bacteremia despite therapy warrants echocardiogram, source review, and ID consultation.

What is a trough level and when should it be drawn?

A vancomycin trough level is the serum concentration at its lowest point, immediately before the next dose. For traditional trough-based monitoring: draw within 30 minutes before the scheduled dose, at steady state (typically after 4–5 doses in patients with normal renal function, or 2–3 days in patients with CKD). Trough target for serious infections using the old approach was 15–20 mcg/mL. In AUC-guided dosing, the trough is one input to estimate AUC, and acceptable trough levels are typically 8–15 mcg/mL when AUC/MIC 400–600 is being targeted.

What are signs of vancomycin toxicity?

Vancomycin-associated nephrotoxicity (VAN) is the primary toxicity concern: rising serum creatinine, decreased urine output, AKI (usually non-oliguric). Risk factors: high AUC, concomitant Pip-Tazo or other nephrotoxins, prolonged therapy, ICU admission, baseline CKD. Historical concern about ototoxicity (hearing loss) has not been well supported by modern evidence when levels are appropriately monitored. Red Man Syndrome (flushing, pruritus) is a rate-related infusion reaction, not true toxicity. Monitor creatinine daily, BUN every 2–3 days, and audiometry if prolonged high-dose therapy is needed.

Is this calculator a substitute for Bayesian software?

No. This provides a simplified first-order pharmacokinetic estimation using a fixed volume of distribution (0.7 L/kg), which may not be accurate for patients with obesity, fluid overload, critical illness, or unusual body composition. For clinical precision, Bayesian AUC monitoring software (e.g., PrecisePK, InsightRX, DoseMeRx) is strongly recommended as it integrates multiple drug levels, patient covariates, and validated population pharmacokinetic models for more accurate AUC estimation. Always consult a clinical pharmacist for vancomycin dosing decisions.

Online Medical Tools — Vancomycin AUC/MIC

Printed on 6/29/2026

For informational purposes only. This is not medical advice.

Infectious Disease

Vancomycin AUC/MIC

The Vancomycin AUC/MIC calculator provides a simplified estimation of the 24-hour area under the curve to minimum inhibitory concentration ratio (AUC₂₄/MIC), which is the recommended pharmacokinetic/pharmacodynamic target for vancomycin therapy per the 2020 ASHP/IDSA/PIDS/SIDP guidelines. The target AUC/MIC of 400–600 (assuming MIC = 1 mg/L) replaces the previous trough-based monitoring approach. This tool uses a first-order pharmacokinetic model with estimated volume of distribution (0.7 L/kg) and elimination rate constant derived from trough levels. For clinical precision, Bayesian AUC monitoring software is preferred. Vancomycin is renally cleared — always check [eGFR Calculator](/tools/egfr-calculator) and [Creatinine Clearance Calculator](/tools/creatinine-clearance) before dosing. Monitor for AKI with [BUN/Creatinine Ratio](/tools/bun-creatinine-ratio). For MRSA sepsis severity, track with [SOFA Score](/tools/sofa-score).

Formula: Simplified first-order PK: Vd = 0.7 L/kg, ke = ln(Cpeak/Ctrough)/interval, CL = ke × Vd, AUC₂₄ = Daily dose / CL.

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Enter weight, age, and creatinine to estimate vancomycin clearance

Vancomycin is almost entirely renally excreted. Estimated creatinine clearance (via Cockcroft-Gault formula) is the primary driver of vancomycin clearance and determines initial dosing interval. Enter actual body weight (or adjusted body weight for obese patients), age, and serum creatinine. Also enter the vancomycin dose, interval, and a trough level drawn appropriately (30 minutes before the next dose at steady state, typically after the 4th or 5th dose).

Calculate initial dose and interval based on renal function

Standard initial dosing is 15–20 mg/kg IV every 8–12 hours for normal renal function. In renal impairment: CrCl 50–90 mL/min → q12h; CrCl 30–50 → q24h; CrCl 15–30 → q48h; CrCl <15 or ESRD → dosing guided by levels (often 15–20 mg/kg when trough falls below 10). A loading dose of 25–30 mg/kg (maximum 3g per dose) is recommended for critically ill patients to rapidly achieve therapeutic levels.

Target AUC/MIC 400–600 per 2020 ASHP/IDSA/SIDP guidelines

The 2020 consensus guidelines recommend AUC-guided monitoring (target AUC/MIC 400–600 assuming MRSA MIC = 1 mg/L) over the older trough-only approach (target 15–20 mcg/mL). AUC-guided dosing reduces nephrotoxicity by 30–50% without compromising efficacy. This calculator provides a simplified first-order estimation — for clinical precision, Bayesian software (PrecisePK, InsightRX, DoseMeRx) and pharmacist consultation are strongly recommended.

Who Uses the Vancomycin AUC/MIC

MRSA Bacteremia Treatment

Infectious disease specialists, hospitalists

Vancomycin is the gold-standard treatment for MRSA bacteremia (methicillin-resistant Staphylococcus aureus bloodstream infection). Appropriate dosing is critical — underdosing leads to treatment failure and resistance, while overdosing causes nephrotoxicity. Duration for uncomplicated MRSA bacteremia is at least 2 weeks of IV vancomycin with repeat blood cultures at 48–72 hours to confirm clearance. Complicated MRSA bacteremia (endocarditis, osteomyelitis, device infection) requires 4–6 weeks.

Hospital-Acquired Pneumonia (HAP/VAP) Dosing

Intensivists, pulmonologists, ICU nurses

Vancomycin covers MRSA in hospital-acquired and ventilator-associated pneumonia. ICU patients have complex pharmacokinetics — increased volume of distribution, augmented renal clearance (in hyperdynamic states), and concurrent nephrotoxins. Standard weight-based dosing may be insufficient, and loading doses are often needed. Monitor AUC/MIC closely with pharmacist collaboration. Lung tissue penetration is limited — achieving target AUC/MIC 400–600 is even more critical for pulmonary MRSA.

Infective Endocarditis

Infectious disease specialists, cardiologists

MRSA native valve endocarditis requires high-dose vancomycin for 6 weeks. The IDSA endocarditis guidelines recommend maintaining AUC/MIC 400–600. Prosthetic valve endocarditis requires vancomycin plus rifampin. AUC-guided monitoring is especially critical in endocarditis — both subtherapeutic dosing (bacteriologic failure) and supratherapeutic dosing (AKI forcing dose reduction) have been associated with worse outcomes. OPAT (outpatient IV therapy) is appropriate for stable patients after initial hospitalization.

Febrile Neutropenia with Gram-Positive Coverage

Hematologist-oncologists, bone marrow transplant teams

Vancomycin is added to empiric febrile neutropenia regimens when gram-positive infection is suspected (central line, MRSA risk factors, severe mucositis). Per IDSA guidelines, vancomycin is NOT routinely added to all febrile neutropenia regimens — only when specific clinical criteria are met. In patients with profound neutropenia and hemodynamic instability, loading doses and AUC-guided dosing are especially important.

Penicillin-Allergic Surgical Prophylaxis

Surgeons, anesthesiologists, perioperative pharmacists

Vancomycin is used for surgical prophylaxis in penicillin-allergic patients undergoing procedures where MRSA coverage or gram-positive prophylaxis is indicated (cardiac surgery, orthopedic implants, neurosurgery). Prophylactic dosing is 15 mg/kg as a single pre-incision dose, given slowly over at least 1 hour to complete before surgical incision. Avoid in patients with true penicillin allergy who have been skin-tested and found safe — cefazolin is superior for most procedures.

Dose Adjustment for Renal Impairment

Nephrologists, clinical pharmacists, hospitalists

Vancomycin requires careful dose reduction in CKD and AKI. Augmented renal clearance (CrCl >130 mL/min) in hyperdynamic critically ill patients requires higher doses and shorter intervals. ESRD patients on hemodialysis typically receive vancomycin 1g after each dialysis session (hemodialysis removes approximately 30–50% per session). CRRT removes variable amounts depending on filter type and effluent rate. Always involve nephrology and pharmacy for complex renal dosing scenarios.

Pro Tips

2020 guidelines: prefer AUC-guided over trough-only monitoring

The 2020 ASHP/IDSA/SIDP guidelines formally recommend AUC/MIC-guided vancomycin monitoring over the older trough-only approach. The target is AUC₂₄/MIC 400–600 (assuming MRSA MIC = 1 mg/L). Maintaining troughs at 15–20 mcg/mL — as was standard practice before 2020 — was associated with 2–3× increased risk of vancomycin-associated nephrotoxicity (VAN) without improving efficacy. AUC-guided dosing achieves target pharmacokinetics at lower average troughs (8–15 mcg/mL), reducing kidney injury while maintaining bactericidal activity.

Loading dose 25–30 mg/kg for critically ill patients

For critically ill patients with suspected or confirmed serious MRSA infections (bacteremia, endocarditis, pneumonia, septic shock), a loading dose of 25–30 mg/kg (maximum 3g per single dose) is recommended to rapidly achieve therapeutic AUC. Without a loading dose, standard dosing may take 3–4 doses (12–48 hours) to reach therapeutic levels — an unacceptable delay in serious infection. The loading dose can be given safely despite the infusion rate concern because Red Man Syndrome is rate-dependent, not dose-dependent.

Infusion rate matters — slow to 10–15 mg/min to prevent Red Man Syndrome

Red Man Syndrome (flushing, erythema of face/neck/chest, sometimes hypotension) is caused by direct mast cell degranulation from rapid vancomycin infusion — it is NOT an IgE-mediated allergy. Standard recommendation: infuse at maximum 10–15 mg/min (or no faster than 1g/30 minutes). For large doses (2–3g), infuse over 2–3 hours. If Red Man Syndrome occurs, slow the infusion rate and give diphenhydramine — do NOT label the patient as 'vancomycin-allergic,' as they can tolerate the medication when infused correctly.

Concomitant piperacillin-tazobactam increases AKI risk 3–4 fold

Multiple studies have demonstrated that combining vancomycin with piperacillin-tazobactam (Pip-Tazo, Zosyn) dramatically increases the risk of acute kidney injury compared to vancomycin alone or vancomycin with other beta-lactams (cefepime, meropenem). Meta-analyses show a 3–4× increased AKI risk with the combination. When empiric broad-spectrum coverage is needed alongside vancomycin, cefepime or meropenem are preferred over piperacillin-tazobactam to reduce nephrotoxicity risk. Monitor [BUN/Creatinine Ratio](/tools/bun-creatinine-ratio) and [eGFR](/tools/egfr-calculator) daily.

Draw trough level 30 minutes before the next dose at steady state

For traditional trough monitoring, the sample must be drawn within 30 minutes before the next dose, and at steady state (typically after 4–5 doses in patients with normal renal function). Early trough levels (before steady state) are unreliable. For AUC estimation, two-level sampling (peak at 1–2 hours post-infusion AND trough) provides more accurate AUC calculation than trough alone. Many centers now use Bayesian estimation with a single level, which is most accurate when combined with prior population PK parameters.

MRSA MIC ≥2 mcg/mL typically indicates vancomycin treatment failure

The IDSA guidelines state that MRSA isolates with vancomycin MIC ≥2 mcg/mL (the breakpoint for intermediate susceptibility, VISA) are associated with treatment failure even with optimized vancomycin dosing. When your MRSA blood culture isolate reports a MIC of 2 mcg/mL, consider alternative agents: daptomycin (for bacteremia, NOT for pneumonia due to surfactant inactivation), ceftaroline, telavancin, or linezolid. Infectious disease consultation is strongly recommended for these cases.

Obese patients require weight-based dosing adjustments

In morbidly obese patients (BMI >40), use adjusted body weight (IBW + 0.4 × [TBW − IBW]) rather than total body weight for initial vancomycin dosing, to avoid overdosing. Vancomycin volume of distribution expands less proportionally than body weight in obesity. However, actual body weight may be needed in some patients. Pharmacokinetics are variable — early therapeutic drug monitoring and pharmacist collaboration are essential for obese patients.

Hemodialysis patients: dose after each session, monitor levels

Patients on intermittent hemodialysis (IHD) are typically dosed with vancomycin after each hemodialysis session — high-flux dialyzers remove approximately 30–50% of vancomycin per session. A common approach: give 1g IV post-HD, then check a pre-HD level before the next session; redose if the level has fallen below 10–15 mcg/mL. For continuous renal replacement therapy (CRRT), vancomycin clearance is more predictable — doses of 500–1000 mg q12-24h are typical, with levels guided by AUC targets.

Check daily BMP when patient is on vancomycin

Vancomycin nephrotoxicity typically manifests as a rise in serum creatinine after several days of therapy. Risk factors include: high AUC (>600), concomitant nephrotoxins (contrast, aminoglycosides, NSAIDs, Pip-Tazo), ICU admission, prolonged therapy, and baseline CKD. Check serum creatinine and BUN daily in hospitalized patients on vancomycin. If creatinine rises more than 0.5 mg/dL (or 50% from baseline), notify pharmacy and infectious disease for dose adjustment. Use [BUN/Creatinine Ratio](/tools/bun-creatinine-ratio) to monitor for AKI pattern.

Oral vancomycin is for C. difficile only — not systemic MRSA

IV and oral vancomycin are NOT interchangeable for most infections. Oral vancomycin is almost completely unabsorbed in patients with an intact gut — it achieves high concentrations in the colon and is the treatment of choice for Clostridioides difficile colitis. However, oral vancomycin does NOT reach therapeutic blood levels and CANNOT treat systemic infections such as MRSA bacteremia or MRSA pneumonia. Always specify the route when ordering vancomycin and educate patients and nursing staff about this important distinction.

Common Questions About Your Results

This is most likely Red Man Syndrome (RMS), NOT a true drug allergy. RMS is caused by direct mast cell degranulation from rapid vancomycin infusion — it is rate-dependent, not immune-mediated. Symptoms include erythema and flushing of the face, neck, and upper chest, with occasional pruritus and hypotension. Treatment: slow or pause the infusion, give diphenhydramine (Benadryl) 25–50 mg IV, and restart at a slower rate when symptoms resolve. Do NOT document as 'vancomycin allergy' — this label causes patients to receive inferior alternative antibiotics for future MRSA infections unnecessarily.

Vancomycin-associated nephrotoxicity (VAN) typically occurs after several days of therapy, especially when AUC exceeds 600 or in the presence of other nephrotoxins (pip-tazo, contrast, NSAIDs). Steps: (1) Check vancomycin AUC/level and reduce dose or extend interval. (2) Discontinue or reduce any concomitant nephrotoxins if safe. (3) Ensure adequate hydration. (4) Check [eGFR](/tools/egfr-calculator) and [BUN/Cr ratio](/tools/bun-creatinine-ratio). (5) Consult pharmacy for PK optimization. (6) Consider switch to alternative anti-MRSA agent if the kidneys are not recovering. VAN is usually reversible with dose adjustment.

Critically ill patients have significantly altered vancomycin pharmacokinetics: increased volume of distribution (from fluid resuscitation, hypoalbuminemia, sepsis), augmented renal clearance in hyperdynamic phases, and rapidly changing renal function. These patients often require higher doses (25–35 mg/kg/day) and more frequent monitoring. A loading dose (25–30 mg/kg) is strongly recommended. Early Bayesian AUC-guided dosing with pharmacist collaboration is essential. Standard weight-based dosing without frequent monitoring often results in subtherapeutic AUC in the first 24–48 hours of critical illness.

ESRD patients on HD do not metabolize vancomycin — they rely entirely on dialysis for elimination. Standard approach: loading dose of 20–25 mg/kg IV (based on actual body weight, maximum 3g) at the initiation of therapy. Check a vancomycin level before the next scheduled HD session — if below 10–15 mcg/mL, redose with 500–1000 mg IV. High-flux dialyzers remove 30–50% of vancomycin per session; low-flux dialyzers remove very little. Know your dialysis membrane. Pharmacist involvement is essential for HD patients, as dosing frequency is unpredictable and depends on residual renal function and dialysis clearance.

Evidence-Based Methodology

Vancomycin dosing follows the 2020 American Society of Health-System Pharmacists (ASHP)/Infectious Diseases Society of America (IDSA)/Society of Infectious Diseases Pharmacists (SIDP) Vancomycin Consensus Guidelines (AJHP 2020). AUC/MIC-guided monitoring is now preferred over trough-only monitoring based on multiple PK/PD studies demonstrating reduced nephrotoxicity without compromising efficacy. MRSA treatment guidelines reference IDSA MRSA Guidelines (Liu et al., CID 2011, updated 2022).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Your estimated AUC/MIC ratio indicates whether the current vancomycin dosing regimen is achieving the therapeutic target. An AUC/MIC of 400-600 (assuming MIC of 1 mg/L) is the recommended target per the 2020 ASHP/IDSA/PIDS/SIDP consensus guidelines. An AUC/MIC below 400 suggests subtherapeutic dosing with risk of treatment failure, particularly in serious MRSA infections such as bacteremia, endocarditis, osteomyelitis, and pneumonia. An AUC/MIC above 600 is associated with increased risk of vancomycin-associated nephrotoxicity.

If your result is outside the target range, dose adjustment is likely needed. Increasing the dose or shortening the interval raises the AUC, while decreasing the dose or extending the interval lowers it. Renal function changes (improving or declining) will also shift the AUC, so ongoing monitoring is essential.

When to Use This Tool

Use this calculator when monitoring vancomycin therapy for serious MRSA infections, particularly when Bayesian AUC monitoring software is not immediately available. It is intended for patients on steady-state vancomycin dosing who have at least one trough level drawn appropriately (within 30 minutes before the next scheduled dose).

This tool is most useful in initial dose optimization, when transitioning from empiric to targeted dosing, or when renal function changes necessitate dose re-evaluation. It should be used in conjunction with clinical pharmacist consultation for patients with complex pharmacokinetics (obesity, renal replacement therapy, critical illness, burns).

Limitations

This calculator uses a simplified first-order pharmacokinetic model with an estimated volume of distribution of 0.7 L/kg, which may not be accurate for patients with obesity, fluid overload, critical illness, or pediatric populations. The true Vd can vary significantly (0.4-1.0 L/kg) depending on patient factors.

For clinical precision, Bayesian AUC monitoring software (such as PrecisePK, InsightRX, or DoseMeRx) is strongly preferred, as these platforms integrate multiple drug levels, population pharmacokinetic models, and individual patient covariates for more accurate AUC estimation. This calculator also assumes an MIC of 1 mg/L — if the actual MIC is 2 mg/L, the effective AUC/MIC is halved, and alternative antibiotics should be considered. Always consult a clinical pharmacist for vancomycin dosing decisions.

For related assessments, see Creatinine Clearance, eGFR Calculator and Centor Score.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Clinical

Creatinine Clearance

Calculate creatinine clearance (CrCl) with Cockcroft-Gault to guide renal medication dose adjustments from age, weight, sex, and serum creatinine.

Open Clinical

eGFR Calculator

Calculate eGFR with the CKD-EPI 2021 race-free formula to estimate kidney function and CKD stage from serum creatinine, age, and sex.

Open Infectious Disease

Centor Score

Calculate the Modified Centor (McIsaac) Score for streptococcal pharyngitis probability. Score 0–1: no testing needed. Score 2–3: rapid strep test. Score 4–5: treat empirically with antibiotics.

Open Pharmacy

Gentamicin Dosing

Calculate gentamicin dose and interval using extended-interval (5–7 mg/kg q24h) or traditional q8–12h dosing methods based on creatinine clearance and adjusted body weight.

Open

Frequently Asked Questions

The 2020 consensus guidelines shifted from trough-based monitoring (target 15–20 mcg/mL) to AUC/MIC-based monitoring (target 400–600) because: (1) AUC/MIC better correlates with clinical efficacy, (2) maintaining trough levels of 15–20 was associated with increased nephrotoxicity, and (3) AUC-guided dosing reduces vancomycin-associated AKI by approximately 30–50%. AUC-guided dosing achieves therapeutic efficacy at lower average trough levels (8–15 mcg/mL), significantly reducing kidney injury risk.

MRSA (methicillin-resistant Staphylococcus aureus) is a strain of Staph aureus that carries the mecA gene, which confers resistance to all beta-lactam antibiotics (penicillins, cephalosporins, carbapenems). Because standard antibiotics don't work, vancomycin — a glycopeptide antibiotic that works by blocking cell wall synthesis via a different mechanism — becomes the first-line treatment. MRSA can cause skin infections, pneumonia, bacteremia, endocarditis, osteomyelitis, and other serious invasive infections.

Vancomycin is primarily used for: (1) MRSA infections — bacteremia, endocarditis, pneumonia, osteomyelitis, septic arthritis; (2) Serious gram-positive infections in penicillin-allergic patients — including streptococcal and enterococcal infections; (3) Clostridioides difficile colitis (oral form only — not absorbed systemically); (4) Surgical prophylaxis in beta-lactam allergic patients or when MRSA risk is high; (5) CNS infections caused by resistant gram-positive organisms (combined with other agents for meningitis). IV vancomycin is for systemic infections; oral is only for C. diff.

AUC-guided vancomycin monitoring typically uses two approaches: (1) Two-level sampling — measure a peak level 1–2 hours after infusion completes AND a trough level 30 minutes before the next dose; enter both into Bayesian software or first-order PK equations. (2) Single trough with Bayesian modeling — enter patient demographics, dose, interval, and trough level into population PK software (PrecisePK, InsightRX, DoseMeRx) which integrates all parameters to estimate individual AUC. Most major centers now use Bayesian software for clinical dosing decisions.

Red Man Syndrome is NOT a true IgE-mediated drug allergy — it is a rate-dependent direct mast cell degranulation reaction to rapid vancomycin infusion. Symptoms: flushing and erythema of the face, neck, and upper chest, pruritus, and occasionally hypotension. It typically begins within minutes of starting infusion. Management: slow or pause the infusion, give diphenhydramine 25–50 mg IV, and restart at a slower rate. Never document Red Man Syndrome as a 'vancomycin allergy' — patients can safely receive vancomycin when infused slowly (over 60–90+ minutes for 1g doses).